RUNX1 mutations and inv(3) are associated with MPP-L, abnormalities of secondary AML with MPP-L and CMP-L, CEBPA mutations, RUNX1-RUNX1T1 or CBFB-MYH11 translocations with GMP-L, NPM1, and TET2 or IDH mutations with GP-L and NPM1 and DNMT3A mutations and t(11q23) with MP-L. This evidence concerns the gene DNMT3A and acute myeloid leukemia.